UK markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
10,800.00-8.00 (-0.07%)
At close: 05:04PM BST
Sign in to post a message.
  • J
    Crypto currency as we all know have been changing lives since many years back, and as a beginner which I am I was very afraid to invest in crypto but however I’ve been reading about it. Few months ago I met Mr Benjamin Richard. who is a professional day trader with his help and signals I made 5 BTC Witt instant successful withdraw. You can reach him via 🆃🅴🅻🅴🅶🆁🅼.
    @ Benjamin_Richard2
  • P
    So is AZN still going to acquire MREO as well?
  • B
    Is AZN still interested in MREO ?
  • P
    Isn’t AZN buying Mereo Pharmaceuticals?
  • r
    AZN looks like it is about to drop. Be careful guys. I have been reading ( and their stocks have been doing way better.
  • V
    They just featured AZN on this sites morning watchlist. (
  • C
    Too many scams out here but I can’t be scared of making money. If its worth the Risk I’m in 💯. I started investing using Jeff Rogers Platform Last Year , he shared his commercial techniques and helped me achieve my goals and now the profit rate is exponential. Contact On. 🆃🅴🅻🅴🅶🆁🅼: (@Jeff_Rogers1) Look Up To Him On Wh@+$@pp +1 (317) 953‑3794
  • C
    Analysts estimate the newly proven drugs in the pipeline will raise AZNs bottom line by 17% over the next year making it a screaming buy here.
  • D
    Is AZN working out deal to buy MREO and their pipeline ?
  • A
    People are taking profit from AZN and moving it to other stocks that has dropped a lot more. AZN was a safety play in the past year since it hasn’t dropped much at all…. Remember in a recession, all stocks go down eventually as it’s needed to reach a bottom
  • W
    DEBTS $33 BB, cash $6 BB, wait for $40!
  • D
    By Jaime Llinares Taboada

    AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

    The pharmaceutical company said Enhertu has been recommended by the EU's Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

    This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

    Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.
  • W
    Time to get lean, not buy a co!!!
    Noooo thanks
  • T
    Hey Froehling what did you say
  • I
    Good news from ASCO on impact of Inhertu on late stage breast cancer.
  • D
    1.85% of institutions would consider $AZN a core holding, constituting over 8% of their portfolio